For example, Luxturna, the groundbreaking in vivo gene therapy for hereditary retinal dystrophy, transfers the RPE65 gene to retinal cells using an AAV vector, and its successful approval confirmed the feasibility of gene therapy 110. Here, RPE65 is linked to Retinal dystrophy.